title: Paradoxical worsening in tuberculosis during therapy in an HIV-infected patient.
authors.forename: A
authors.initials: A
authors.lastname: Mofredj
authors.forename: J M
authors.initials: JM
authors.lastname: Guérin
authors.forename: F
authors.initials: F
authors.lastname: Leibinger
authors.forename: R
authors.initials: R
authors.lastname: Masmoudi
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000009:adverse effects* / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000009:adverse effects* / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D010996:Pleural Effusion / Q000150:complications*; D011241:Prednisone / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy*; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D015215:Zidovudine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D004977:Ethambutol; D007538:Isoniazid; D011241:Prednisone; D012293:Rifampin